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Abstract
Background: Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control
primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The
objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC.
Methods: FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over
3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC
with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline
surgery. Radiotherapy treatment planning is undertaken using four dimensional CT scanning to incorporate the
impact of respiratory motion. Treatment must be delivered using a conformal or intensity modulated technique
including IMRT, VMAT, Cyberknife or Tomotherapy. The trial includes two alternate fractionation schedules based on
tumour size: for tumours ≤4 cm in maximum diameter a single fraction of 26Gy is delivered; and for tumours >
4 cm in maximum diameter 42Gy in three fractions is delivered. The primary outcome of the study is to estimate
the efficacy of SABR for primary RCC. Secondary objectives include estimating tolerability, characterising overall
survival and cancer specific survival, estimating the distant failure rate, describing toxicity and renal function
changes after SABR, and assessment of cost-effectiveness of SABR compared with current therapies.
Discussion: The present study design allows for multicentre prospective validation of the efficacy of SABR for
primary RCC that has been observed from prior single institutional and retrospective series. The study also allows
assessment of treatment related toxicity, overall survival, cancer specific survival, freedom from distant failure and
renal function post therapy.
Trial registration: Clinicaltrials.gov NCT02613819, registered Nov 25th 2015.
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Background
Renal cell carcinoma and SABR
Primary renal cell carcinoma (RCC) is the 9th most com-
mon cancer in Australia [1] and 8th most common world-
wide [2]. In Australia there has been an 88% increase in
the age-standardised incidence of RCC in the period from
1982 to 2014 [1]. The standard of care for fit patients with
localised kidney cancer is surgical resection of the kidney
(nephrectomy). However, patients undergoing partial or
total nephrectomy for renal cancer experience post-opera-
tive nephron loss, which may result in new chronic kidney
disease or advancement of pre-existing renal dysfunction
[3, 4]. Additionally, since the mean age of onset is 65
years [1], many patients have coexisting medical issues
that preclude them from major surgery. Presently, these
patients have limited curative treatment options. Non-sur-
gical treatment options for this population of patients in-
clude radiofrequency ablation (RFA) and cryotherapy.
These thermal techniques have significant limitations.
They can typically only treat smaller tumours which need
to be away from the collecting system and vascular struc-
tures due to the risk of heat sink effects, stricture and/or
fistula development [5]. Treatment of larger tumours
poses significant risks of haemorrhage, which can require
a nephrectomy to control [5]. Both RFA and cryotherapy
are costly and dependent on user technician proficiency
and availability. Both are invasive, with access through in-
cisions in the skin. Thus, patients with inoperable primary
RCC, particularly those with larger tumours, represent a
group in need of an effective non-invasive alternative to
surgery.
Stereotactic ablative body radiotherapy (SABR) is emer-
ging as a non-invasive method for precision irradiation
of tumours using doses with a higher biological effect
than can be achieved with conventional radiotherapy.
SABR does not necessitate inpatient hospital admis-
sion, is delivered in a single or relatively few treatment
sessions, and is typically associated with a low toxicity
and excellent local control rates in a variety of malig-
nancies [6]. This radioablative technique represents a
radical departure from conventional fractionated radio-
therapy that is delivered with many treatments (frac-
tions) over several weeks. SABR offers patients who are
unable or unwilling to undergo surgery an effective al-
ternative which can potentially prolong survival. SABR
is now well established and widely utilised in the treat-
ment of tumours of the brain, lung, liver, and spinal
column [7–10].
In order to test this potential benefit of this technique
in a larger randomised study, the initial step is to ro-
bustly establish efficacy of SABR for primary RCC. This
multicentre phase II trial aims to validate the efficacy
readout previously established by a pilot study con-
ducted in the Australian setting [11].
Existing knowledge
RCC is generally considered “radioresistant” in the con-
text of conventionally fractionated radiotherapy. How-
ever, the capacity to deliver ablative doses of radiation
accurately with SABR has shifted this paradigm [12].
The Karolinksa Institute in Sweden have the first re-
ported clinical cases utilising SABR in the treatment of
renal tumours, having treated kidney targets since the
early 1990’s [13]. Wersall et al. [35] reported a retro-
spective series of 50 patients with metastatic renal can-
cer and 8 patients with inoperable primary tumours
treated with SABR. Using a dose fractionation of 8Gy ×
4, 10Gy × 4 and 15Gy × 3 they achieved a local control
rate of 90–98%. 39% of patients developed at least one
side effect, with 50% of registered side effects being
grade I-II. In 2012 our group published a systematic re-
view of 126 patients indicating favourable early results
from SABR for primary RCC, with local control rates
ranging from 84 to 100% and severe treatment related
toxicities (grade 3+) of 3.8% [14]. Modern single institu-
tional prospective reports from our centre [15, 16] and
collaborators [17–19] corroborate these findings with
very infrequent severe treatment related toxicities (<
5%). These studies report local control rates of 87% in
15 patients [19], 95% in 19 patients [17] and 100% in 30
RCC patients [18]. These findings are summarised in
Table 1. A further recent study addressed the role of
SABR in large primary RCC (those with a median
tumour diameter of 9.5 cm) [20]. With a median follow
up 3.9 years, there was one treatment related grade 3
event but no grade 4 or 5 toxicities. Importantly, in
these studies, unlike RFA and cryotherapy, SABR was
not limited to smaller tumours (< 4 cm) or those located
away from central pelvic calyceal structures. Finally, the
International Radiosurgery Oncology Consortium for
the Kidney (IROCK) [21] published pooled results of
223 patients in 2018, with a 2-year local control rate of
97.8% [22].
Addressing an unmet clinical need
As RCC is a disease typically of an older population, in
routine clinical practice some patients are not fit for sur-
gery due to existing co-morbidities. These patients need
an effective non-invasive alternative to surgery to control
their kidney disease. A multicentre, multinational clinical
trial is warranted to assess the efficacy of SABR as a
treatment option for primary RCC in medically inoper-
able patients or those who decline surgery.
Methods/design
Study objectives and hypothesis
The primary objective of this study is to estimate the ef-
ficacy of SABR for primary RCC. The primary endpoint
is freedom from local progression, as defined by lack of
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progression of the target lesion (primary RCC) as mea-
sured by RECIST criteria [66]. The primary hypothesis
of this study is that freedom from local progression at
1-year post-treatment will be > 80%.
Key secondary endpoints include assessment of a)
Toxicity, as measured by CTCAE v4.03; b) Overall sur-
vival; c) Cancer specific survival; d) Freedom from dis-
tant failure; e) Renal function measured by serum
Table 1 Review of SABR literature for primary RCC



















33 17 Median 40Gy in
5 fractions
94% 92 NR NR
Lo et al.
[9] 2014







15 36.7 Median 33Gy in
3 fractions
87%
1 failure at 30.7 mo
1 failure at 31.2 mo
NR NR 1 x Grade 3
renal toxicity
5 x Grade 1
fatigue













Qian et al. [29]
2003 (abstract)
20 12 40Gy in 5 fractions 93% 86 NR NR
Pham et al. [15]
2014 [prospective]
20 6 26Gy in 1 fraction 42Gy
in 3 fractions
NR NR NR 60% Grade 1–2
No Grade 3,
Grade 4
Ponksy et al. [30]
2015 [prospective]
19 13.7 Max 48Gy in 4 fractions NR NR NR 5.2% Grade 2,
15.8% Grade 3–4
Siva et al. [16]
[prospective]
33 24 26Gy in 1 fraction 42Gy
in 3 fractions





5 52 40Gy in 4 or 5 fractions,
45Gy in 3 fractions






7 39 40Gy in 4 fractions 86% 91 NR 58% Grade 1–2,
nil else
Teh et al. [33]
2007 (abstract)













9 38.3 36-51Gy to 50% isodose
line at 3-5Gy per fraction
5 year LC 43% NR 5 year OS 35% Early: 44%
Grade 1 (GI, haem.)
Late: 22% Grade 2 (GI)
Wersall et al.
[34] 2005
8 37 40Gy in 4 or 5 fractions,
45Gy in 3 fractions
100% 100 Median survival
58+ months
20% Grade 1–2,
19% Grade 3, nil
Grade 4+
a report included an additional 15 patients with Transitional cell carcinoma;
b pooled results with patients treated for TCC
NR not reported, Gy Gray
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creatinine and estimated glomerular filtration rate
(eGFR) using CKI-EPI equation, split function and cal-
culated glomerular filtration rate (GFR) on nuclear
medicine testing; f ) Cost-effectiveness. An exploratory
objective is to assess the utility of multi-parametric
MRI (mpMRI) as a biomarker of treatment response
in a subset of patients.
This trial will be conducted in radiation oncology
treatment centres throughout Australia, the MAASTRO
clinic in the Netherlands, and the Royal Marden Hos-
pital in England. All participating centres must success-
fully complete pre-trial quality assurance procedures
prior to enrolling patients to the study. This will consist
of an initial credentialing phase involving phantom dos-
imetry audit, facility questionnaires and a plan quality
benchmarking exercise. Real-time quality assurance
through plan reviews will be performed as part of the
trial.
Study design
The Trans-Tasman Radiation Oncology Group (TROG)
15.03 FASTRACK II clinical trial is a single arm, multi-
institutional phase II study conducted in collaboration
with the Australian and New Zealand Urogenital and
Prostate Cancer Trials Group (ANZUP). The trial will
recruit 70 participants over a 3-year period, with patient
follow-up to 5 years from the end of accrual. All partici-
pants will receive SABR as definitive treatment for their
primary RCC.
The study population is patients with biopsy con-
firmed primary RCC with a single lesion within a kidney.
The intervention is a single fraction SABR with one of
two fractionation schedules selected based on tumour
size: a single fraction of 26Gy is used for tumours ≤4 cm
in maximum diameter, with 42Gy in three fractions de-
livered for tumours > 4 cm in maximum diameter. While
biological equivalent dose estimation based on linear
quadratic formula can be unreliable to estimate the ef-
fect of doses >10Gy per fraction, this model is still the
most commonly used to describe iso-effectiveness of al-
ternate SABR fractionation regimens. The radiosensitiv-
ity of the two most common human RCC cell lines
(Caki-1 and A498) has been observed in the laboratory
to vary with α/β values estimated to be 2.6Gy or 6.9Gy,
depending on the cell line [23]. The biological effective
dose for tumour effects when using the dose/fraction-
ation cohorts proposed with an α/β of 6.9Gy are 123Gy
for 26Gy in 1 fraction, and 127Gy for 42Gy in 3 frac-
tions. When altering the model to use the alternate α/β
of 2.6Gy, the biological equivalent dose is 286Gy for
26Gy in 1 fraction and 268Gy for 42Gy in 3 fractions.
These dose calculations show that the cohorts are rela-
tively iso-effective across a reasonable range for potential
tumour effects in the study.
Inclusion / exclusion criteria
To participate in the trial, patients must meet all of the
following key inclusion criteria at randomisation:
 Age ≥ 18 years old
 Biopsy confirmed diagnosis of RCC with no more
than a single lesion within a kidney (bilateral RCC is
allowable ECOG performance ≤2
 Life expectancy > 9 months
 Either medically inoperable, technically high risk for
surgery or decline surgery
 Provide written informed consent
 A multidisciplinary decision has been made that
active treatment is warranted
Key exclusion criteria are listed below:
 Pre-treatment estimated glomerular filtration rate
< 30 mls/min
 Prior systemic therapies for RCC
 Previous high-dose radiotherapy to an overlapping
region (defined as BED >40Gy using an α/β ratio
of 10)
 Tumours larger than 10 cm in maximum dimension
 Direct contact of the target tumour with bowel
 Untreated prior malignancy, or prior malignancy
within 2 years of screening
 Visceral / bony metastatic disease
 Horseshoe kidney
Sample size and study duration
In total, 70 patients are required for this study. It is
anticipated that it will take 36 months to complete
target accrual. The sample size of 70 patients was
chosen to provide sufficiently narrow confidence in-
tervals for clinical outcomes. If up to 15% of partici-
pants do not proceed to treatment, or die or are lost
to follow-up before experiencing a local progression
in the first year, and assuming the freedom from local
progression (FFLP) at 1-year is 90%, the correspond-
ing two-sided 95% confidence interval will be 79–
96%. A 1-year freedom from local progression of 80%
or less will be considered undesirable and not worthy
of proceeding to a future randomised study against
other treatment modalities. The freedom from local
progression at 1-year is expected to be around 90%.
With those assumptions, the proposed sample size
will have 80% power with 10% alpha to test the null
hypothesis that the FFLP at 1-year is 80% or less.
The study end date is deemed to be the date of last
data capture, which will be when the final participant
completes the 5 year follow-up visit. Participant as-
sessments are tabulated in Table 2.
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Radiotherapy treatment regimen
All participants are to be adequately immobilised using,
at a minimum, a half body vacuum immobilisation
device. A 4DCT scan in treatment position is used to ac-
count for respiratory motion. Target volumes accounting
for respiratory motion and setup uncertainty must be
defined as below:
 Internal Target Volume (ITV) – The ITV must be
contoured taking the total tumour excursion
through respiration into account.
 Planning Target Volume (PTV) – ITV to PTV
margins must take into consideration set-up
uncertainties. A 5 mm expansion isotropic
expansion from ITV to PTV must be used.










































GFR (Cr-51 EDTA) j












✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
QLQ-C30
questionnaire m
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓m
Adverse Event
Reporting







aTo be done within 8 weeks of registration
bTreatment to commence within 6 weeks of registration
cCalculated from the date of the last radiotherapy fraction given. Post treatment follow-up to continue until both local and distant progression has been recorded
dAfter participant has both local and distant progression documented, annual survival status will be collected
eTo be done at both local and distant progression
fAfter participant has both local and distant progression documented, annual survival status will be collected until study closure
gAustralian Participants only for consent to access outpatient medical and pharmaceutical services via the MBS and PBS
hWith or without contrast
iCT to include pelvis at pre-registration & progression scans. The target lesion size determined from the pre-registration scan CT will dictate the fractionation
schedule to be prescribed
j- Where split function cannot be performed by DMSA SPECT/CT, a MAG-3 study should be performed
- Calculated GFR through Cr-51 EDTA measurement or equivalent should be performed at this time point whenever possible, if this study is available
- This should be the same study for all investigations time points
- After the 60 month post follow-up visit, these are to be performed biennially until study completion
kBlood test include - full blood count (FBE), serum urea and electrolytes (UEC’s), c-reactive protein (CRP) and estimated glomerular filtration rate (eGFR)
lDetermined by the CKD-EPI equation
mQLQ-C30 questionnaire is to be completed post progression until participant reached 5 years post treatment
nParticipating sites only
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For fractionated treatment schedules, treatment frac-
tions are expected to be delivered on non-consecutive
days (approximately 48 h apart). All treatment should be
completed within 3 weeks.
Dose criteria
The investigational treatment will be prescribed to the
covering isodose, ensuring that 99% of the PTV is cov-
ered by 100% of the dose (D99PTV = 100%). In the cir-
cumstance where doses to organs at risk (OAR) cannot
be respected whilst achieving this level of coverage, an
alternative prescription coverage of D95PTV = 100% is
acceptable. The peak dose (DMax) should be
ideally 125%, resulting in a normalised equivalent cover-
ing isodose of 80%. The acceptable isodose at the per-
iphery is expected to be between 70 and 80%. Peak dose
(Dmax) should not exceed 143%. OAR constraints are
found in Table 3.
Treatment delivery
3D conformal treatment must be delivered with at least
six non-opposing conformal megavoltage photon beams.
It is anticipated that a typical range of beam numbers
would be 8 to 12, comprising of at least 6 co-planar
beams and 1–2 non-coplanar beams. For treatment with
conformal or VMAT arc techniques a typical beam ar-
rangement would include two 180–220 degree arcs
avoiding entrance through the contralateral side. A rep-
resentative treatment plan is demonstrated in Fig. 1.
Treatment verification
All patients must undergo daily online image verifica-
tion. Verification imaging must be capable of visualising
the target with soft tissue matching as well as bone
alignment. This would necessitate imaging with a Cone
Beam CT (CBCT) or superior pre-treatment imaging
modality.
On-trial quality assurance (QA) program
This trial includes a comprehensive on-trial QA pro-
gram. A pre-treatment radiotherapy QA technical review
will be undertaken by the trial management team to pro-
vide independent validation of target definition, OAR
contouring and plan quality. Post-treatment radiother-
apy QA technical review will also be undertaken for all
participating cases.
To ensure high plan quality and adherence to OAR
dose limits, treatment plans will be assessed using know-
ledge based planning (KBP) prior to treatment. A Rapid-
Plan model in the Eclipse treatment planning software
(Varian Medical Systems, Palo Alto, USA) will be cre-
ated based on the first 55 kidney SABR patients treated
at Peter MacCallum Cancer Centre. The model will be
applied to the first 20 patients recruited to the current
trial to determine applicability to various planning sys-
tems and techniques used in this multi-centre trial. The
model will then be used to determine if sufficient spar-
ing of OARs has been achieved for each patient enrolled
in the trial, based on previously achieved plan quality.
This information will be communicated to the indi-
vidual centres with the option to change the treat-
ment plan prior to treatment if deemed appropriate
given potential plan quality improvements and time
and resource limitations.
Adverse event reporting
All adverse events (AE) are to be reported between base-
line and completion of study follow-up. All non-serious
adverse events (including anticipated and unanticipated
device related adverse events) shall be recorded in the
trial database via adverse event CRFs. Internal statistical
analysis of this data shall be performed at the times spe-
cified in the protocol and investigators and responsible
HRECs will be advised of any safety issues which emerge
Table 3 Organ at Risk Constraints
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a Ipsilateral Kidney minus ITV should adhere to the ALARA principle. In
particular, investigators should focus on minimising high dose regions (> 50%
isodose) outside the ITV but within the ipsilateral kidney
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during this process. Serious adverse event (SAEs) are to
be reported to the Trial Coordinating Centre by the trial
site within 24 h of being identified, from the commence-
ment of radiotherapy to 90 days after the last fraction of
radiotherapy. The investigator is responsible for notify-
ing the responsible HRECs and Research Governance
Officers as per local ethical and regulatory guidelines.
Imaging sub-study 1: Evaluation of renal function change
in response to SABR
Preservation of renal function is a major objective of kid-
ney SABR. We will obtain split function nuclear medicine
studies at baseline and 12, 24, 42 and 60 months after
SABR for each patient enrolled in this trial. We will use
deformable image registration to register the CT compo-
nent of each DMSA SPECT/CT with the treatment plan-
ning CT, and apply this registration to the SPECT data.
This will result in a 3D map of the DSMA uptake in the
same spatial frame of reference as the planned radiother-
apy dose. Based on this, we will then determine the
change in DSMA uptake with radiation dose, and link any
change as observed on imaging with clinical toxicity. Un-
derstanding the renal toxicity dose response will inform
dose constraints on future patients. This information can
further be used to optimise treatment plan quality in fu-
ture renal SABR patients to minimise the dose to the
functional components of the kidney.
Imaging sub-study 2: Evaluation of renal function change
in response to SABR
Multiparametric MRI (mpMRI) including diffusion
weighted imaging (DWI) and dynamic contrast enhanced
(DCE) MRI will be acquired in a subset of patients before
treatment (baseline) and at 3 months and 12 months after
SABR. DWI will be obtained using an echo-planar im-
aging sequence in the coronal plane with b-values of 50,
400 and 800 mm2/s, with the use of respiratory gating to
reduce the effect of motion. DCE MRI will be obtained
using a 3D T1-weighted TWIST sequence, in the coronal
plane at an oblique angle so the entire affected kidney and
the aorta are within the field of view. DCE MRI will be ac-
quired during free breathing and 3D motion correction al-
gorithms will be applied afterwards to reduce the effect of
motion. Apparent diffusion coefficient (ADC) maps will
be computed from the DWI data, and semi-quantitative
and pharmacokinetic maps computed from DCE MRI
data. Tumour contours will be drawn on the ADC maps
and DCE MRI data, and relevant parameter statistics ex-
tracted. The change in each MRI parameter will be com-
puted relative to baseline MRI, and correlated with the
changes in tumour volume shown on follow-up CT relative
to baseline CT, to assess whether DWI or DCE MRI pa-
rameters indicate treatment response earlier than conven-
tional morphological CT based measures given by RECIST
criteria [24] as shown in our exploratory study [25].
Health economics evaluation
An economic evaluation will be conducted to estimate
the incremental cost-effectiveness of SABR compared
with current therapies (RFA/cryotherapy/surgery) for the
treatment of patients with RCC. In the first instance, this
will assess the within study costs and outcomes associ-
ated over the 5 years of the study. Subsequently, a Mar-
kov model will be developed using data on SABR from
FASTRACK II and historical data on the comparators to
assess the incremental cost-effectiveness of SABR com-
pared with current therapies for the treatment of inoper-
able RCC.
The outcomes of the economic evaluation will be pre-
sented as cost per additional quality adjusted life year
(QALY) gained. For SABR, QALYs will be estimated by
applying utility values derived from the QLQ-C30 [26]
by the time spent in each health state (e.g. progression
free, progressed) and summed to calculate the total
number of QALYs associated with SABR throughout the
defined time-horizon. Utility values for the comparator
Fig. 1 Axial 3D conformal treatment plan of SABR for right kidney (A) and 3D reconstruction (B) showing multiple beam angles resulting
in high-doses wrapping tightly around the target
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technologies will be sought from the literature. In the
absence of published values for those technologies, it
will be assumed that there is no difference in utility
values between therapies for a given health state.
Costs will be estimated taking into account the direct
health care resources used for the delivery of SABR, as-
sociated hospital visits and the use of other medical ser-
vices. Australian patients will be consented for access to
administrative claims data from Medicare in order to
capture outpatient medical and pharmaceutical services.
Indirect patient costs (e.g. travel time and clinic time
away from usual activities) will be assessed via a patient
completed questionnaire, to be administered at the time
of completing HRQoL questionnaires. Costs for the
comparators will be based on existing scheduled fees
and hospital costs known to apply to current therapies,
supplemented with information on outpatient service
use as informed by the data from this study.
Resource use will be valued using hospital-specific costs
and scheduled fees for medical services and procedures.
Mean estimates of costs will be used and Bayesian cred-
ibility intervals (BCI) will be generated by boot-strapping
the data. The robustness and validity of the cost-effective-
ness analysis will be explored using both a deterministic
one-way sensitivity analysis and a probabilistic sensitivity
analysis.
Statistical considerations
Baseline characteristics will be summarised using descrip-
tive statistics including counts and percentages for cat-
egorical variables and mean, standard deviation (SD),
median and range for continuous variables. The Kaplan-
Meier method will be used to estimate the OS, FFLP and
freedom from distant progression. Annual estimates will
be provided alongside 95% CI. An exploratory analysis will
be carried out assessing the impact of baseline and treat-
ment characteristic on OS using a Cox proportional haz-
ard model. Cumulative incidence curves for cancer related
death will be provided assuming competing risks with
non-cancer related death as a competing event. Cumula-
tive incidence curve for Grade 3+ toxicity will be provided
assuming competing risks with death not related to treat-
ment considered as a competing risk. A table with the fre-
quency of worst AE grade experienced will also be
provided for each individual AE type.
Change over time in renal function (serum creatinine,
eGFR using CKI-EPI equation, split renal function and
calculated GFR using nuclear medicine assessments) will
be described using linear mixed models. The linear mixed
model will include time as fixed effect (as a factor) and pa-
tients as a random effect. Mean and 95% confidence inter-
vals will be calculated for each time point and the data
will be displayed graphically using contrast from the linear
mixed models. Changes from baseline will also be
estimated using contrast from the linear mixed model.
The impact of medical factors on renal function decline
will be assessed by including relevant variables as inde-
pendent variables in the linear mixed model.
No imputation of missing values and no adjustments for
multiplicity are intended. This trial aims to a) describe
clinical outcomes of patients with RCC treated with SABR
and b) assess whether it is worthwhile conducting a future
large randomised trial against other treatment modalities.
The descriptive part of the study will use 5% alpha to pro-
vide two-sided 95% confidence intervals for clinical out-
comes while the hypothesis testing on the FFLP at 1 year
will use a one sided test with 10% alpha.
Discussion
There is growing evidence to support the safety of
SABR/SRS, its effect on local control and possible im-
pact on overall survival for primary RCC. FASTRACK II
is a study that will provide multicentre validation of the
efficacy of SABR, which has previously only been dem-
onstrated in single institutional and retrospective re-
ports. At the time of writing, the study is open at eight
sites across Australia and is actively recruiting, with two
international sites in the process of activation. TROG
15.03 FASTRACK II will provide robust data on the effi-
cacy of SABR for primary RCC in inoperable patients, to
enable future larger phase III clinical trials.
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